Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock closed at 138.88 per share at the end of the most recent trading day (a -0.1% change compared to the prior day closing price) with a volume of 768.38K shares and market capitalization of 16.29B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1453 people. Alnylam Pharmaceuticals Inc. CEO is John M. Maraganore.

The one-year performance of Alnylam Pharmaceuticals Inc. stock is 8.6%, while year-to-date (YTD) performance is 6.86%. ALNY stock has a five-year performance of 101.89%. Its 52-week range is between 119.29 and 178.41, which gives ALNY stock a 52-week price range ratio of 33.14%

Alnylam Pharmaceuticals Inc. currently has a PE ratio of -19.10, a price-to-book (PB) ratio of 16.45, a price-to-sale (PS) ratio of 40.27, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.54%, a ROC of -52.31% and a ROE of -66.47%. The company’s profit margin is -%, its EBITDA margin is -141.40%, and its revenue ttm is $393.38 Million , which makes it $3.35 revenue per share.

Of the last four earnings reports from Alnylam Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.73 for the next earnings report. Alnylam Pharmaceuticals Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Alnylam Pharmaceuticals Inc. is Moderate Buy (1.71), with a target price of $173.32, which is +24.80% compared to the current price. The earnings rating for Alnylam Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alnylam Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alnylam Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.67, ATR14 : 6.96, CCI20 : -5.54, Chaikin Money Flow : 0.01, MACD : -4.56, Money Flow Index : 42.40, ROC : 2.78, RSI : 41.42, STOCH (14,3) : 57.10, STOCH RSI : 0.97, UO : 42.38, Williams %R : -42.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alnylam Pharmaceuticals Inc. in the last 12-months were: Akshay K. Vaishnaw (Option Excercise at a value of $1 009 565), Akshay K. Vaishnaw (Sold 23 912 shares of value $3 358 416 ), Barry E. Greene (Option Excercise at a value of $1 163 880), Barry E. Greene (Sold 89 060 shares of value $12 389 297 ), John M. Maraganore (Option Excercise at a value of $1 194 507), John M. Maraganore (Sold 138 274 shares of value $19 035 968 ), Laurie B. Keating (Option Excercise at a value of $5 722 504), Laurie B. Keating (Sold 81 976 shares of value $13 025 838 ), Phillip A. Sharp (Option Excercise at a value of $279 000), Phillip A. Sharp (Sold 30 000 shares of value $3 746 748 ), Steven M. Paul (Option Excercise at a value of $139 500), Steven M. Paul (Sold 15 000 shares of value $2 100 000 ), Yvonne Greenstreet (Option Excercise at a value of $16 662 719), Yvonne Greenstreet (Sold 234 497 shares of value $36 325 955 )